Tier 2 — API & Excipients Manufacturing

Tier 2 — API & Excipients Manufacturing
Product Description

Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.

Read more Show less

Ministry of Health, The United Republic of Tanzania

  • Country/Region:
    Tanzania, United Republic of
  • Founded:
    1961
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    5000+
Company types
Other
Primary activities
Other
View company profile
Categories
more categories Show less
Specifications
  • Details
    Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.
  • Selling Points
    Tier 2 — API & Excipients Manufacturing▸Opportunity — zero API manufacturing capacity in the entire EAC region; 100% of APIs currently imported.▸Strategic priority — designated by TMDA and PIAT as a medium-to-long-term focus; highest policy priority.▸Investment range — USD 50-200M for scaled API production; enables industrial sovereignty.
  • Model
    Opportunity — zero API manufacturing capacity in the entire EAC region;
More specifications Fewer specifications

Ministry of Health, The United Republic of Tanzania

  • Country/Region:
    Tanzania, United Republic of
  • Founded:
    1961
  • On CPHI since:
    2026
  • Certificates:
    1
  • Employees:
    5000+
Company types
Other
Primary activities
Other
View company profile

More Products from Ministry of Health, The United Republic of Tanzania (2)

  • Tier 1 — Essential Medicines Manufacturing

    Product Tier 1 — Essential Medicines Manufacturing

    Opportunity — substitute 20-40% of the USD 800M-1B annual import bill. Target WHO-GMP-compliant production of human medicines for infectious and non-infectious diseases including anti-TB, anti-cancer, ARVs, first-line anti-malarials.▸Market assurance — 15% MSD procurement preference; framework agreements; ...
  • Tier 4 — Small Volume Parenterals

    Product Tier 4 — Small Volume Parenterals

    Tier 4 — Small Volume Parenterals▸Opportunity — no ampoules or vials manufacturing in Tanzania. Huge demand across hospitals, immunisation, emergency medicine.▸Investment range — USD 20-60M for a compliant facility.

Ministry of Health, The United Republic of Tanzania resources (1)

  • Tanzania's Pharmaceutical Investment Acceleration Taskforce Arrives at CPHI China in Shanghai, Inviting Global Manufacturers to Africa's Emerging Production Hub

    News Tanzania's Pharmaceutical Investment Acceleration Taskforce Arrives at CPHI China in Shanghai, Inviting Global Manufacturers to Africa's Emerging Production Hub

    Shanghai, 15 June 2026 — A delegation from Tanzania's Pharmaceutical Investment Acceleration Taskforce (PIAT), the Government's whole-of-government mechanism for fast-tracking strategic pharmaceutical investment, has arrived in Shanghai for CPHI China 2026, held at the Shanghai New International Expo Center from 16 to 18 June. The delegation will engage directly with international manufacturers, active pharmaceutical ingredient (API) producers, and contract manufacturing organisations to present Tanzania's case as Africa's next pharmaceutical manufacturing hub.
    CPHI China is Asia's leading pharmaceutical trade event, convening suppliers and buyers across the entire supply chain — making it a natural venue for Tanzania's outreach to the manufacturers best positioned to establish production capacity on the continent.

    "Tanzania is ready to become Africa's pharmaceutical manufacturing hub. The direction is clear. The commitment is firm. The time is now," 

    14 Jun 2026